This meta-analysis also showed that the association between pCR and EFS was strongest in patients with triple-negative breast cancer (TNBC) and in patients with HER2-positive, hormone receptor–negative tumors who received trastuzumab23. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.